Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Gold

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Gastroenterology|November 26, 2009
What's causing this woman's chest pain?Tara Iyengar, Ramesh K Ramanathan, Philip J Gold
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2010
Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)Philip J Gold, Bryan Goldman, Syma Iqbal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2013
First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinomaAndrew X Zhu, Philip J Gold, Anthony B El-Khoueiry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancerNeal J Meropol, Philip J Gold, Robert B Diasio, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Syma Iqbal, Cathryn Rankin, Heinz-Josef Lenz, et al.
Investigational New Drugs|July 13, 2011
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinomaAnthony B El-Khoueiry, Cathryn J Rankin, Edgar Ben-Josef, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2012
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)Michael B Tomblyn, Bryan H Goldman, Charles R Thomas, et al.
Investigational New Drugs|October 23, 2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Robert P Whitehead, Cathryn Rankin, Paulo M G Hoff, et al.
Cancer Research Communications|March 27, 2023
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)Aaron J Scott, Atrayee Basu Mallick, Efrat Dotan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinomaLawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Gastroenterology|November 26, 2009
What's causing this woman's chest pain?Tara Iyengar, Ramesh K Ramanathan, Philip J Gold
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2010
Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)Philip J Gold, Bryan Goldman, Syma Iqbal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2013
First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinomaAndrew X Zhu, Philip J Gold, Anthony B El-Khoueiry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancerNeal J Meropol, Philip J Gold, Robert B Diasio, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Syma Iqbal, Cathryn Rankin, Heinz-Josef Lenz, et al.
Investigational New Drugs|July 13, 2011
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinomaAnthony B El-Khoueiry, Cathryn J Rankin, Edgar Ben-Josef, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2012
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)Michael B Tomblyn, Bryan H Goldman, Charles R Thomas, et al.
Investigational New Drugs|October 23, 2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Robert P Whitehead, Cathryn Rankin, Paulo M G Hoff, et al.
Cancer Research Communications|March 27, 2023
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)Aaron J Scott, Atrayee Basu Mallick, Efrat Dotan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinomaLawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
Pageof 3